Back to search results

MRI and Biomarkers for Lung Nodules in Lung Cancer Screening

This observational study is looking at how well people join and stay in research that uses Lung MRI (magnetic resonance imaging) and Blood Draws to find lung nodules during lung cancer screening. Researchers want to see if it's practical to recruit and keep participants for future studies on these methods. You might be able to join if you are 50 or older, have a history of smoking (20 pack-years or more), and are currently in a lung cancer screening program. The main goal is to measure how many people join and stay in the study over 3 years. The current status of this study is unclear.

Study design
This is an observational study planning to enroll 30 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo a Lung MRI and a Blood Draw. The duration of your participation is not specified, but the study measures retention over 3 years.
Compensation
Not stated in the trial record.
Follow-up
The study measures participant retention for 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05699213

MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening

UNKNOWN
Not specifiedAges 50+Observational
Cedars-Sinai Medical Center
~30 participants
Updated 2023-08-30 on ClinicalTrials.gov
What's tested:Lung MRIBlood Draw

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Accrual and Retention Rate
Measured over 3 years

Conditions

Lung Cancer

Explore related trials

Lung Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Sara Ghandehari, MD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai

Who to contact

Weijia Chua, MD
[email protected]
310-423-1838
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to read and understand informed consent
Male or female adults who are at high risk for lung cancer and are enrolled in the centralized lung cancer screening program: Based on USPSTF guidelines: Age 50-80 with 20 or greater pack-year smoking story who continue to smoke or quit within the past 15 years without sign or symptoms of lung cancer. Or based on National Comprehensive Cancer Network (NCCN) guidelines but do not meet the USPSTF guidelines, age 50-unlimited
Found to have one or more lung nodules that is 6mm or greater on screening LDCT

Exclusion

Persons with an active diagnosis of cancer
Persons with active signs or symptoms of lung cancer
Persons with mechanically, magnetically, or electrically activated implants, such as cardiac pacemakers, neurostimulators, and infusion pumps.
Persons with ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged.
Persons who are pregnant, nursing, are implanted with intrauterine devices (IUD's) that are not MR-compatible
Persons unable to tolerate MRI imaging secondary to an inability to lie supine or severe claustrophobia.
Persons who are non-compliant with visit instructions, including inability to lie still, hold breath or follow procedure instructions

What this trial measures

  • Accrual and Retention Rate3 years

    The primary outcome measure is the accrual and retention rate of a study population from a centralized lung cancer screening program to support MRI and blood-based biomarker research.